Use of Pharmaceutical Nanotechnology in Treatment of Covid-19: A Systematic Review Study
Journal of Pharmaceutical Negative Results
; 13:184-192, 2022.
Article
in English
| Web of Science | ID: covidwho-2072530
ABSTRACT
Background:
The pathogenesis of SARS-CoV-2 is not fully understood, and currently there is currently no definitive drug or treatment against it. So, the drugs used to treat SARS-CoV-2 are mainly based on their effectiveness on previous species of coronaviruses. This review aimed to evaluate the studies performed on the use of the available drugs in the treatment of Covid-19 since the onset of this disease.Method:
Comprehensive search strategy was conducted in the following databases PubMed, Web of Science (IR) and Scopus, Psycinfo, Google Scholar, and national databases, including Scientific Information Database (SID) and Maglran from inception of Covid-19 to June 2022. Studies that reported the effect of different drugs in treatment of Covid-19 patients were included.Results:
38 studies (114,552 participants) were included in this systematic review study on used drug treatment of patients with Covid-19 including Remdesivir, HCQ & Chloroquine, Favipiravir, Molnupiravir, Arbidol, Kaletra, Oseltamivir, IVIG & Interferon.Conclusions:
Remdesivir, HCQ & Chloroquine, Favipiravir, Molnupiravir, Arbidol, Kaletra, Oseltamivir, IVIG & Interferon are the most commonly used drugs in treatment of Covid-19. Although these drugs may be effective in improving the condition of Covid-19 patients in the inflammatory phase, the confirmation of their use requires more extensive clinical research.
Full text:
Available
Collection:
Databases of international organizations
Database:
Web of Science
Type of study:
Reviews
/
Systematic review/Meta Analysis
Language:
English
Journal:
Journal of Pharmaceutical Negative Results
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS